Literature DB >> 28396816

PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings.

Michael Froehner1, Marieta Toma2, Klaus Zöphel3, Vladimir Novotny1, Michael Laniado4, Manfred P Wirth1.   

Abstract

A 67-year-old man diagnosed with Gleason score 4 + 5 = 9 clinically localized prostate cancer with 68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) positive Paget bone disease is described. Immunohistochemical staining revealed weak PSMA positivity of the bone lesion supporting the hypothesis that neovasculature might explain positive PSMA-PET/CT findings in Paget disease.

Entities:  

Year:  2017        PMID: 28396816      PMCID: PMC5370467          DOI: 10.1155/2017/1654231

Source DB:  PubMed          Journal:  Case Rep Urol


1. Introduction

68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) is a valuable tool in the workup of patients with prostate cancer presenting with the suspicion of metastatic disease [1-3]. The sensitivity and specificity of PSMA-PET/CT for overall bone involvement in patients with prostate cancer have been found to be 99-100% and 88–100%, respectively [4]. In view of these high sensitivity and specificity values of this imaging modality, false-positive findings may create diagnostic pitfalls.

2. Case Presentation

An asymptomatic 67-year-old man was diagnosed with Gleason score  4 + 5 = 9  clinically localized prostate cancer (prostate-specific antigen, PSA, 6.7 ng/mL). A bone scan revealed increased pelvic tracer uptake that was considered suspicious for Paget disease (Figure 1(a)). 68Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) showed moderate PSMA positivity of this lesion (Figure 1(b)). Since Paget disease has been reported to cause PSMA positivity bone lesions [5-8], a bone biopsy was obtained for final workup that confirmed the diagnosis of Paget disease (Figure 2). After radical prostatectomy (pT3bpN0), PSA fell below the lowest detection level ruling out gross bone metastases. Six months after surgery, PSA was still undetectable and no symptoms of Paget disease were present.
Figure 1

Bone scan showing increased uptake in the left-sided pelvis suggestive for Paget disease (a). Computed tomography demonstrated coarsened and bloated pubic bone (b). The lesion showed moderate uptake of 68Ga-labeled prostate-specific membrane antigen-targeted ligand (maximal standardized uptake value up to 13.8) (c). The maximal standardized uptake value of the primary tumor in the prostate was 10.0.

Figure 2

CT-guided biopsy (a) showed irregular bone structure with fibrotic marrow spaces ((b) H&E; original magnification ×20) containing multinucleated giant cells ((c) arrowheads; chloroacetate esterase stain; original magnification ×20). Immunohistochemical staining for PSMA revealed weak PSMA expression in endothelial cells ((d) arrowhead; original magnification ×20) in the Paget bone lesion.

3. Discussion

Paget disease is a common disorder of the skeleton characterized by hypertrophic and abnormally structured remodeling of bone [9, 10]. Many patients are asymptomatic, whereas others suffer from pain, nerve compression, or even pathologic factures. Rarely, malignant degeneration (osteosarcoma) may occur [9, 10]. Genetic and environmental factors play a role in the pathogenesis [10]. Bisphosphonates are used for treatment; it is, however, unknown whether they influence the national history of the disease [10]. Endothelial expression of PSMA in neovasculature known to occur in Paget disease has been postulated as the mechanism causing the PSMA-PET/CT positivity of this condition [5-8]. In the current case, we found some confirming evidence for this assumption with a weak PSMA positivity of endothelial cells in the bone affected by Paget disease (Figure 2(d)). Paget disease is a common disorder affecting up to 3% of senior adults [9]. PSMA-PET/CT positivity seems to be a usual phenomenon in Paget disease [5-8] that should be taken into consideration when PSMA-PET/CT is used during workup of patients with prostate cancer in order to avoid a pitfall in this otherwise accurate and sensitive diagnostic tool [1-3]. Beside Paget disease, various other tumors [11], coeliac ganglia [12], splenosis [13], sarcoidosis [14], and subacute stroke [15] have been reported to cause false-positive PSMA-PET imaging findings.
  15 in total

1.  Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Authors:  C Artigas; J Alexiou; C Garcia; Z Wimana; F-X Otte; T Gil; R Van Velthoven; P Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-27       Impact factor: 9.236

Review 2.  Biology and Treatment of Paget's Disease of Bone.

Authors:  Mahéva Vallet; Stuart H Ralston
Journal:  J Cell Biochem       Date:  2015-09-03       Impact factor: 4.429

3.  Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT.

Authors:  Benjamin Noto; Alexis Vrachimis; Michael Schäfers; Lars Stegger; Kambiz Rahbar
Journal:  Clin Nucl Med       Date:  2016-10       Impact factor: 7.794

4.  Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone.

Authors:  Sophie Bourgeois; Pieterjan Gykiere; Lode Goethals; Hendrik Everaert; Frank W De Geeter
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

5.  68Ga-PSMA PET/CT False-Positive Tracer Uptake in Paget Disease.

Authors:  Arun Sasikumar; Ajith Joy; Raviteja Nanabala; M R A Pillai; Hari T A
Journal:  Clin Nucl Med       Date:  2016-10       Impact factor: 7.794

Review 6.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Marlon Perera; Nathan Papa; Daniel Christidis; David Wetherell; Michael S Hofman; Declan G Murphy; Damien Bolton; Nathan Lawrentschuk
Journal:  Eur Urol       Date:  2016-06-28       Impact factor: 20.096

7.  Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy.

Authors:  Michael Froehner; Klaus Zöphel; Tobias Hölscher; Michael Laniado; Manfred P Wirth
Journal:  Urology       Date:  2016-04-25       Impact factor: 2.649

8.  Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer.

Authors:  Thomas Pyka; Shozo Okamoto; Marielena Dahlbender; Robert Tauber; Margitta Retz; Matthias Heck; Nagara Tamaki; Markus Schwaiger; Tobias Maurer; Matthias Eiber
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-12       Impact factor: 9.236

9.  68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.

Authors:  Annika Herlemann; Vera Wenter; Alexander Kretschmer; Kolja M Thierfelder; Peter Bartenstein; Claudius Faber; Franz-Josef Gildehaus; Christian G Stief; Christian Gratzke; Wolfgang P Fendler
Journal:  Eur Urol       Date:  2016-01-19       Impact factor: 20.096

10.  Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance.

Authors:  Hai-long Wang; Shao-shan Wang; Wen-hui Song; Yi Pan; Hai-peng Yu; Tong-guo Si; Yong Liu; Xiao-nan Cui; Zhi Guo
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

View more
  5 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 2.  The Value of Multimodality PET/CT Imaging in Detecting Prostate Cancer Biochemical Recurrence.

Authors:  Jie Jiang; Xiaoxia Tang; Yongzhu Pu; Yong Yang; Conghui Yang; Fake Yang; Yadong Tian; Jindan Li; Hua Sun; Sheng Zhao; Long Chen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

Review 3.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 4.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

5.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.